PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SRPT vs. ML
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SRPT and ML is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

SRPT vs. ML - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sarepta Therapeutics, Inc. (SRPT) and MoneyLion Inc. (ML). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%NovemberDecember2025FebruaryMarchApril
-62.67%
-70.58%
SRPT
ML

Key characteristics

Sharpe Ratio

SRPT:

-0.93

ML:

0.38

Sortino Ratio

SRPT:

-1.49

ML:

1.12

Omega Ratio

SRPT:

0.79

ML:

1.16

Calmar Ratio

SRPT:

-0.80

ML:

0.32

Martin Ratio

SRPT:

-2.16

ML:

0.89

Ulcer Index

SRPT:

24.96%

ML:

32.60%

Daily Std Dev

SRPT:

57.66%

ML:

76.13%

Max Drawdown

SRPT:

-98.17%

ML:

-97.57%

Current Drawdown

SRPT:

-67.21%

ML:

-76.69%

Fundamentals

Market Cap

SRPT:

$5.69B

ML:

$979.19M

EPS

SRPT:

$2.34

ML:

$0.76

PE Ratio

SRPT:

25.05

ML:

113.82

Total Revenue (TTM)

SRPT:

$1.49B

ML:

$424.90M

Gross Profit (TTM)

SRPT:

$1.21B

ML:

$356.78M

EBITDA (TTM)

SRPT:

$247.43M

ML:

$37.39M

Returns By Period

In the year-to-date period, SRPT achieves a -51.80% return, which is significantly lower than ML's 0.57% return.


SRPT

YTD

-51.80%

1M

-43.02%

6M

-50.65%

1Y

-53.82%

5Y*

-8.97%

10Y*

14.85%

ML

YTD

0.57%

1M

-1.02%

6M

133.59%

1Y

22.52%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SRPT vs. ML — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRPT
The Risk-Adjusted Performance Rank of SRPT is 55
Overall Rank
The Sharpe Ratio Rank of SRPT is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 77
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 66
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 77
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 11
Martin Ratio Rank

ML
The Risk-Adjusted Performance Rank of ML is 6868
Overall Rank
The Sharpe Ratio Rank of ML is 6868
Sharpe Ratio Rank
The Sortino Ratio Rank of ML is 6969
Sortino Ratio Rank
The Omega Ratio Rank of ML is 7070
Omega Ratio Rank
The Calmar Ratio Rank of ML is 6868
Calmar Ratio Rank
The Martin Ratio Rank of ML is 6464
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SRPT vs. ML - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and MoneyLion Inc. (ML). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SRPT, currently valued at -0.93, compared to the broader market-2.00-1.000.001.002.003.00
SRPT: -0.93
ML: 0.38
The chart of Sortino ratio for SRPT, currently valued at -1.49, compared to the broader market-6.00-4.00-2.000.002.004.00
SRPT: -1.49
ML: 1.12
The chart of Omega ratio for SRPT, currently valued at 0.79, compared to the broader market0.501.001.502.00
SRPT: 0.79
ML: 1.16
The chart of Calmar ratio for SRPT, currently valued at -0.80, compared to the broader market0.001.002.003.004.005.00
SRPT: -0.80
ML: 0.32
The chart of Martin ratio for SRPT, currently valued at -2.16, compared to the broader market-10.00-5.000.005.0010.0015.0020.00
SRPT: -2.16
ML: 0.89

The current SRPT Sharpe Ratio is -0.93, which is lower than the ML Sharpe Ratio of 0.38. The chart below compares the historical Sharpe Ratios of SRPT and ML, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50NovemberDecember2025FebruaryMarchApril
-0.93
0.38
SRPT
ML

Dividends

SRPT vs. ML - Dividend Comparison

Neither SRPT nor ML has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SRPT vs. ML - Drawdown Comparison

The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum ML drawdown of -97.57%. Use the drawdown chart below to compare losses from any high point for SRPT and ML. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2025FebruaryMarchApril
-67.21%
-76.69%
SRPT
ML

Volatility

SRPT vs. ML - Volatility Comparison

Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 35.73% compared to MoneyLion Inc. (ML) at 2.48%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than ML based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
35.73%
2.48%
SRPT
ML

Financials

SRPT vs. ML - Financials Comparison

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and MoneyLion Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab